Investment

#Biopharmaceuticals #Immunology / Virology & Vaccines #Investment #invoX Pharma #mRNA #mRNA-based vaccines #Next generation sequencing #Sino Biopharmaceutical

pHion to progress its lead program into the clinic 

invoX Pharma, a UK-based wholly-owned subsidiary of Sino Biopharmaceutical, with an advancing pipeline of innovative products, has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.   pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary… Read More

#Business & Investment #News

#Funding #Investment #Private investment #Seed funding

DDW Highlights Podcast for 30 May 2023 now live

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The theme of DDW’s news review this week is money. Although Clarivate has reported a recent… Read More

#News

#Funding #Investment #Private investment #Seed funding

This week in drug discovery (22-26 May)

News round-up for 22-26 May by DDW Digital Content Editor Diana Spencer. The theme of our news review this week is money. Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and… Read More

#News

Seed fund
#BioInnovation Institute #Denmark #Immunotherapy #InProTher #Investment #Oncology #Seed funding #Start-ups

Danish immunotherapy start-up raises €6M seed funding

Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumours, into clinical development. Incubated at the BioInnovation Institute (BII) and seeded… Read More

#Business & Investment #News #Start-up Zone

Antibiotics
#ABPI #Antibiotics #Antimicrobial resistance (AMR) #Investment #UK government

UK government invests £39 million in AMR research

The UK government will invest up to £39 ($48) million in antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF). The funding includes up to £25 ($30.9) million awarded to support the early development of new antibiotics, vaccines, rapid diagnostics and other products to… Read More

#Editor's Choice #News

#Artificial intelligence (AI) #Funding #Investment #Medicinal chemistry #Neurology #Oncology #PharmEnable

$7.5M investment to target cancer and neurological diseases

PharmEnable has closed a pre-series A investment round of $7.5 million to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi Tanabe Pharma Group. There was also participation… Read More

#Business & Investment #News

#Biopharma #Biotech #Clarivate #Collaboration #Investment #Partnership

Biopharma investment drops by nearly 50% in 2022

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff. The report combines data and… Read More

#Business & Investment #News #Trends & Analysis

Science connection and networking
#Biopharmaceuticals #BioTrinity #Comment #Events #Funding #Investment #Life sciences

Reflecting on BioTrinity 2023  

BioTrinity 2023 marked the 17th annual edition of BioTrinity and took place in London, UK from Tuesday 25 April to Wednesday 26 April. DDW’s Megan Thomas spoke with attendees, and comments on the event.    Fundraising and investment   Coming out of a global pandemic, in-person events initially added a degree… Read More

#Exclusive Content

#BioIndustry Association #Biotechnology #Clarivate #Funding #Investment #Private investment #UK

UK biotech sector raised £295 million in first quarter of 2023

The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence, venture investment remained steady,… Read More

#Business & Investment #Market Reports #News

#BioInnovation Institute #Drug discovery #Funding #Investment #Start-ups

Global start-ups: where is the innovation?

Listen to this article on the DDW Podcast: DDW takes a look at some key global activity taking place around the world for drug discovery and life sciences start-ups. UK Budget a ‘shot in the arm’ for oncology start-ups Before the UK announced its Spring Budget, UK BioIndustry Association (BIA) called… Read More

#Exclusive Content #Start-up Zone

Medical researcher
#Funding #Genetics / genomics #Investment #Paediatrics #Rare disease #SynaptixBio

‘Virtual’ biotech targets R&D funding on rare disease therapy

UK biotech firm SynaptixBio has secured £13.2 million to fund its development of the world’s first treatment for TUBB4A-related leukodystrophy, a rare, incurable and deadly disease. The company successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the last two years. It… Read More

#Business & Investment #News

Computer in laboratory
#Cancer research #Funding #Investment #Mosaic Therapeutics #Oncology #Wellcome Sanger Institute

Company raises $28m to develop targeted cancer therapies

Mosaic Therapeutics has closed its $28 million series A funding round and appointed former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies. Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Diversity
#Clinical trial design #Clinical trials #Diversity #Inato #Inclusivity #Investment #Oncology

$20 million in new funding to make clinical trials more inclusive

Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements. The company will… Read More

#Business & Investment #News #Start-up Zone

Seed fund
#Biologics / Biotechnology #Funding #Investment #SolasCure #Wound care

SolasCure secures £10.9m funding to develop Aurase Wound Gel

Biotechnology company SolasCure has completed its £10.9m ($13.3m) Series B investment round. The funding round was led by Seneca Partners and also included BRAIN Biotech, EVA Pharma, Jonathan Milner, and Wealth Club. SolasCure's first investigational product, Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots which aims… Read More

#Business & Investment #News

Chancellor Jeremy Hunt and the Spring Budget
#Association of the British Pharmaceutical Industry #BioIndustry Association #Investment #Life sciences #MHRA #Regulatory #UK #UK budget #UK government

UK Spring Budget a ‘vote of confidence’ in UK life sciences

There was some good news for the UK life sciences sector in the government’s Spring Budget, but did it go far enough? DDW’s Diana Spencer takes a look at the industry’s reaction. There wasn’t much to write home about in the UK government’s Spring Budget, described by Bloomberg UK’s Marcus… Read More

#Business & Investment #Exclusive Content